Aurobindo Pharma

Aurobindo Pharma share price plunges 7% as margins weigh on Q4 results

Aurobindo Pharma Q4 results 2026: Aurobindo Pharma has reported a 2 per cent rise in consolidated profit after tax to ₹920.84 crore in the fourth quarter ended March 31.

Stocks to watch today: ITC, Maruti Suzuki, Nykaa, LIC, LG Electronics

Stocks to Watch today, May 22, 2026: Nykaa, LIC, ITC, Honasa Consumer, and Maruti Suzuki are some of the key stocks to watch today

Nandish Shah of HDFC Sec suggests Bear Spread on Nifty; key levels here

Nandish Shah of HDFC Securities has shared a Bear Spread strategy on Nifty, and a Bull Spread strategy on Aurobindo Pharma.

Q4 results: ITC, Nykaa, LIC, MTNL, Aurobindo Pharma, and 181 more on May 21

Q4FY26 company results: Firms including Max Healthcare, Gail (India), Prestige Estates, Sun TV, Bikaji Foods International, Quick Heal and Icra are also to release their January-March earnings today

Pharma cos brace for soft Q4; US drag persists; domestic growth cushions

Pharma sector may see a 7 per cent Y-o-Y growth in reported sales and a 1 per cent increase in Ebitda, led by steady ex-gRevlimid US sales, healthy domestic growth, and favourable forex movements

Ex-date alert! Aurobindo Pharma, 3 others to remain in spotlight next week

Notably, Indian equity markets will remain closed on Tuesday, April 14, on account of Dr Baba Saheb Ambedkar Jayanti.

Stocks to Watch today: Rate sensitives, Infosys, Aurobindo Pharma, GAIL

Stocks to Watch today, April 8, 2026: Banks, Real estate, automobiles, Infosys, Aurobindo Pharma are some of the key stocks to watch today

Stocks to Watch today: Godrej Consumer, Aurobindo Pharma, IRFC, PC Jeweller

Stocks to Watch today, April 7, 2025: Godrej Consumer, Aurobindo Pharma, IRFC, ACME Solar Holdings, PC Jeweller, and Titagarh Rail are some of the key stocks to watch today

Aurobindo Pharma sets April 12 as record date for ₹800 crore buyback

Company to repurchase up to 54.24 lakh shares at Rs 1,475 apiece through tender offer route, with promoters also eligible to participate in the buyback

Aurobindo up 4%; stock hits 52-week high, outperforms in 2026; here's why

Aurobindo Pharma to evaluate and consider a proposal for the buyback company's fully paid-up equity shares in its board meet on April 6.

Granules, Aurobindo Pharma among top stocks to buy today; check targets

Kunal Kamble, senior technical research analyst at Bonanza, has recommended buying shares of Aurobindo Pharma, Granules India, and Wheels India today

Aurobindo gains 3%, stock hits 52-week high; JM Financial sees more upside

In the past one month, Aurobindo has outperformed the market by surging 9 per cent, as compared to 8.5 per cent decline in the BSE Sensex.

Trading guide: Check key Nifty levels to watch; two stocks to buy today

According to Vinay Rajani of HDFC Securities, the stock price of Aurobindo Pharma has broken out from the bullish flag pattern on the daily chart

Bharti Airtel, Aurobindo Pharma are top stock picks for today; here's why

Stocks to buy today: Bharti Airtel, and Aurobindo Pharma are the top stock picks by Rajesh Bhosale of Angel One

Stocks to Watch today: Tata Steel, Tech Mahindra, Varun Bev, Shree Cement

Stocks to Watch today, March 18: Tata Steel, Tech Mahindra, Varun Beverages, Shree Cement, and Aurobindo Pharma are among the top stocks to watch today

Stocks to Watch today: ACME Solar, Gravita India, Kalpataru, Raymond Realty

Stocks to Watch today, March 13: Aurobindo Pharma, Godrej Properties, KPI Green Energy, JK Lakshmi Cement, Max Financial Services, and Nectar Lifesciences are among the top stocks to remain in focus

Nifty, Bank Nifty outlook; Aurobindo Pharma, ABB among top stock picks

Bank Nifty has to hold above 56,750 zones for a bounce towards 57,250 then 57,500 levels while a hold below the same could see some weakness towards 56,500 then 56,250 zones

Aurobindo arm launches Pomalidomide generic in US, adds to oncology line

Aurobindo Pharma subsidiary Eugia Pharma has launched generic Pomalidomide Capsules in the US, one of the first-to-file applicants for the drug, expanding its oncology portfolio

Aurobindo Pharma shares rise 4% after incorporating Engenra Biologics arm

The newly formed entity will operate in the pharmaceuticals sector and has been set up to expand the company's contract manufacturing and other pharmaceutical manufacturing operations

Expect Pen-G production capacity to touch 10k MT in 12 months: Aurobindo

Aurobindo Pharma is looking to ramp up the production of Penicillin-G to over 10,000 metric tonnes on an annual basis over the next 12 months, according to company CFO S Subramanian. The Hyderabad-based drug maker also expects its China-based manufacturing plant to break even in EBITDA in Q4 and meaningfully contribute to the bottom-line EBITDA in the next year. "The ramp-up of the facility (Pen-G) is progressing in line with expectations and is well-positioned to deliver a meaningful uplift in profitability over time. Based on our current production level, we expect to produce more than 10,000 metric tonnes on an annualised basis over the next 12 months," Subramanian told analysts in a call. The company's Pen-G facility, located in a SEZ at Kakinada in Andhra Pradesh, is expected to touch production capacity of 15,000 metric tonnes per annum over a period of time. "It is important to note that the yield levels are steady and improving consistently over time," Subramanian said. Th